Hypertension

Hypertension – High-Yield Study Guide for Medical Students

Definition

Hypertension is a chronic elevation of systemic arterial blood pressure associated with increased cardiovascular, cerebrovascular, and renal morbidity and mortality. Contemporary guidelines define it based on office blood pressure (BP) and, where available, out-of-office measurements.

• Normal: <120 / <80 mmHg
• Elevated (high-normal): 120–129 / <80 mmHg
• Stage 1 HTN: 130–139 or 80–89 mmHg
• Stage 2 HTN: ≥140 or ≥90 mmHg

Diagnosis requires repeated elevated measurements on separate visits, or confirmation by ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) to distinguish true hypertension from white-coat or masked hypertension.[7](https://europepmc.org/article/MED/41809280)

Epidemiology

Hypertension is one of the most prevalent non-communicable diseases worldwide and a leading modifiable risk factor for myocardial infarction, stroke, heart failure, chronic kidney disease, and death.[7](https://europepmc.org/article/MED/41809280)

• Prevalence increases with age, higher in patients with obesity, diabetes, and CKD.
• Urbanization, sedentary lifestyle, high-salt diet, and increased stress contribute to rising rates in low- and middle-income countries.
• Medical students and young adults may already demonstrate elevated BP associated with stress, poor sleep, physical inactivity, smoking, and unhealthy diet.[7](https://europepmc.org/article/MED/41809280)
• Hypertension is more common and often more severe in certain ethnic groups and clusters with other cardiovascular risk factors (dyslipidemia, insulin resistance).

Pathophysiology

Hypertension is multifactorial, involving complex interactions between genetic predisposition, environmental factors, neurohormonal systems, and vascular structure and function.

Key Mechanisms

• Increased sympathetic nervous system activity:
  • Chronic overactivity increases heart rate, contractility, and peripheral vascular resistance.
  • Contributes to vasoconstriction, arterial stiffness, and sodium retention.
• Renin–angiotensin–aldosterone system (RAAS) activation:
  • Renin from juxtaglomerular cells converts angiotensinogen to angiotensin I.
  • ACE converts angiotensin I to angiotensin II, a potent vasoconstrictor that also stimulates aldosterone release.
  • Aldosterone increases sodium and water reabsorption, expanding intravascular volume and raising BP.
• Endothelial dysfunction:
  • Reduced nitric oxide and prostacyclin, increased endothelin-1.
  • Shifts the balance toward vasoconstriction, inflammation, and thrombosis.
• Vascular remodeling and stiffness:
  • Chronic pressure load leads to medial hypertrophy, increased collagen, and decreased elastin.
  • Results in increased pulse pressure and systolic hypertension, especially in older adults.
• Renal sodium handling:
  • Impaired pressure natriuresis; kidneys require higher BP to excrete a given sodium load.
  • High salt intake in salt-sensitive individuals markedly worsens BP control.
• Genetic and epigenetic factors:
  • Polygenic contributions affecting ion channels, RAAS components, sympathetic regulation, and vascular tone.
  • Environmental exposures (diet, stress, inactivity) modulate gene expression.

Long-standing hypertension causes target-organ damage: left ventricular hypertrophy, coronary artery disease, heart failure, cerebrovascular disease (ischemic and hemorrhagic stroke), hypertensive retinopathy, nephrosclerosis, and peripheral arterial disease.[7](https://europepmc.org/article/MED/41809280)

Clinical Presentation

Hypertension is typically a silent disease and often discovered incidentally.

• Asymptomatic in most patients, even at moderately high BP.
• Non-specific symptoms (often not reliably correlated with mild to moderate BP elevation):
  • Headache (especially occipital, early morning)
  • Dizziness, lightheadedness
  • Fatigue, reduced exercise tolerance
  • Palpitations
• Symptoms/signs suggesting target-organ involvement:
  • Angina, dyspnea on exertion or orthopnea (ischemia, LV dysfunction, HF)
  • Transient neurologic deficits, visual changes (TIA, stroke, retinopathy)
  • Nocturia, edema, symptoms of CKD
  • Claudication (peripheral arterial disease)
• Signs on physical exam:
  • Elevated BP on correctly performed measurements in both arms
  • LV heave, S4 gallop (LVH)
  • Funduscopic changes (AV nicking, cotton-wool spots, hemorrhages, papilledema in severe HTN)
  • Carotid or peripheral bruits, diminished peripheral pulses

Diagnosis

The diagnosis of hypertension is based on accurate BP measurement and confirmation of persistent elevation. A thorough evaluation should also search for secondary causes and assess cardiovascular risk and target-organ damage.[7](https://europepmc.org/article/MED/41809280)

Accurate Blood Pressure Measurement

• Use appropriately sized cuff; patient seated, back supported, feet flat on floor, arm at heart level.
• Patient should avoid caffeine, exercise, and smoking for at least 30 minutes before measurement.
• Allow 5 minutes of rest before readings.
• Take ≥2 readings spaced 1–2 minutes apart, average them; repeat on ≥2 separate visits.
• Measure both arms at least once; use higher arm for monitoring.

Office vs Out-of-Office BP

• Ambulatory BP monitoring (ABPM):
  • Gold standard for diagnosis; provides 24-hour profile and nighttime BP.
  • Helps detect white-coat and masked hypertension.
• Home BP monitoring (HBPM):
  • Useful for ongoing management, improving adherence and detection of white-coat effects.

Classification (Adult Office BP)

• Normal: <120 and <80 mmHg
• Elevated: 120–129 and <80 mmHg
• Stage 1: 130–139 or 80–89 mmHg
• Stage 2: ≥140 or ≥90 mmHg

Initial Evaluation

Goals are to confirm hypertension, identify contributing/secondary causes, quantify cardiovascular risk, and detect target-organ damage.

• History:
  • Duration and prior BP readings
  • Lifestyle factors: diet (salt, alcohol), physical activity, tobacco, illicit drugs
  • Medication review: NSAIDs, oral contraceptives, steroids, decongestants, stimulants, calcineurin inhibitors, erythropoietin
  • Symptoms of secondary causes: snoring/apnea (OSA), episodic headache/palpitations (pheochromocytoma), muscle weakness/polyuria (hyperaldosteronism), weight change/cushingoid features, renal disease symptoms
  • History of CVD, CKD, diabetes, dyslipidemia, stroke, PAD
  • Family history of early CVD or HTN
• Physical exam:
  • BMI, waist circumference
  • Complete cardiovascular and peripheral vascular exam
  • Fundoscopy for retinopathy
  • Abdominal bruits, renal size, features of endocrine disorders (Cushing, hyperthyroidism, hypothyroidism, acromegaly)
• Basic laboratory work-up:
  • Serum electrolytes, BUN, creatinine, eGFR
  • Fasting lipid profile
  • Fasting glucose or HbA1c
  • Urinalysis (protein, blood), urine albumin-to-creatinine ratio
  • ± TSH, uric acid depending on context
• Additional tests:
  • ECG for LVH, ischemia, arrhythmias
  • Echocardiogram if signs/symptoms of LV dysfunction, HF, or to assess LV mass and structure

When to Suspect Secondary Hypertension

• Onset <30 years with severe HTN and no family history
• Resistant HTN (uncontrolled on ≥3 drugs including a diuretic)
• Sudden worsening of previously stable BP
• Hypokalemia, abdominal bruits, recurrent flash pulmonary edema, or specific endocrine features

Common causes include renal parenchymal disease, renovascular disease, primary aldosteronism, obstructive sleep apnea, pheochromocytoma, Cushing syndrome, thyroid disorders, and coarctation of the aorta.

Management

Management aims to reduce BP to target levels, prevent or regress target-organ damage, and reduce overall cardiovascular risk. It combines lifestyle modification for all patients with pharmacologic therapy when indicated.[7](https://europepmc.org/article/MED/41809280)

Lifestyle Modification (Non-Pharmacologic Therapy)

• Weight reduction:
  • Target BMI 18.5–24.9 kg/m²; even 5–10% weight loss can significantly lower BP.
• Dietary changes:
  • DASH-style diet: high in fruits, vegetables, low-fat dairy; reduced saturated fats.
  • Sodium restriction: aim <2–2.3 g sodium/day where tolerated.
  • Increase dietary potassium (unless CKD or on RAAS inhibitors with hyperkalemia risk).
• Physical activity:
  • ≥150 minutes/week of moderate-intensity aerobic exercise plus resistance training 2–3 days/week.
• Alcohol moderation:
  • Limit to ≤1 drink/day for women and ≤2 for men if drinking.
• Smoking cessation:
  • Does not directly lower BP dramatically but substantially reduces overall CVD risk.
• Stress management and sleep hygiene:
  • Address sleep duration and quality; poor sleep and long daytime napping are associated with adverse cardiovascular markers, such as QTc prolongation, in hypertensive adults.[3](https://pubmed.ncbi.nlm.nih.gov/41782102)

Pharmacologic Therapy

Choice of initial agent depends on age, comorbidities, race/ethnicity, and presence of specific indications. Most patients eventually require ≥2 drugs to reach BP targets.

First-Line Drug Classes

• Thiazide or thiazide-like diuretics
  • Examples: hydrochlorothiazide, chlorthalidone, indapamide.
  • Mechanism: inhibit Na-Cl cotransporter in distal convoluted tubule, promoting natriuresis and reducing plasma volume; long-term effect via decreased peripheral vascular resistance.
  • Side effects: hyponatremia, hypokalemia, hyperuricemia, hyperglycemia, mild LDL/TG increase.
• ACE inhibitors (ACEIs)
  • Examples: lisinopril, enalapril, ramipril.
  • Mechanism: block conversion of angiotensin I to angiotensin II; decrease vasoconstriction and aldosterone.
  • Indications: diabetes with albuminuria, CKD with proteinuria, LV systolic dysfunction, post-MI.
  • Side effects: cough, angioedema, hyperkalemia, rise in creatinine (monitor).
• Angiotensin receptor blockers (ARBs)
  • Examples: losartan, valsartan, candesartan.
  • Mechanism: block AT1 receptor, preventing angiotensin II effects.
  • Similar benefits to ACEIs; used when ACEI intolerance (e.g., cough).
  • Side effects: hyperkalemia, renal function changes; lower risk of cough/angioedema than ACEIs.
• Calcium channel blockers (CCBs)
  • Dihydropyridines: amlodipine, nifedipine (mainly vasodilators).
  • Non-dihydropyridines: diltiazem, verapamil (also affect heart rate and contractility).
  • Mechanism: inhibit L-type calcium channels in vascular smooth muscle and myocardium.
  • Side effects: edema, flushing, headache (dihydropyridines); bradycardia, constipation, AV block (verapamil/diltiazem).

Other Important Drug Classes

• Beta-blockers:
  • Examples: metoprolol, bisoprolol, carvedilol, atenolol.
  • Not first-line for uncomplicated HTN but indicated in CAD, post-MI, arrhythmias, and certain forms of HF.
• Mineralocorticoid receptor antagonists (MRAs):
  • Examples: spironolactone, eplerenone.
  • Useful in resistant hypertension and primary aldosteronism; monitor potassium and renal function.
• Others:
  • Alpha-blockers (doxazosin), central alpha-2 agonists (clonidine), direct vasodilators (hydralazine, minoxidil) are usually reserved for resistant or specific situations.

BP Targets

Targets may vary slightly by guideline, but generally:

• <130/80 mmHg in most adults at high cardiovascular risk or with established CVD, diabetes, or CKD.
• Individualize targets in very elderly or frail patients, or where aggressive lowering may cause adverse effects.

Special Considerations

• Hypertensive urgency vs emergency:
  • Urgency: severely elevated BP without acute target-organ damage – managed with oral agents and gradual reduction over hours to days.
  • Emergency: severe BP elevation with acute target-organ damage (e.g., encephalopathy, MI, pulmonary edema, aortic dissection) – requires immediate parenteral therapy and close monitoring.
• Young adults and students:
  • High stress, irregular sleep, poor diet, and sedentary behavior increase early risk of elevated BP and future hypertension.[7](https://europepmc.org/article/MED/41809280)
  • Early detection and lifestyle optimization are crucial in this group.
• Comorbid conditions:
  • In CKD with proteinuria, ACEIs or ARBs are preferred to slow progression.
  • In diabetes, ACEIs/ARBs, thiazides, and CCBs have good outcome data; avoid agents that worsen metabolic control if possible.

Monitoring and Follow-up

• Reassess BP 4–12 weeks after initiating or adjusting therapy, more frequently if severe or unstable.
• Monitor electrolytes and renal function after starting or modifying diuretics, ACEIs, ARBs, or MRAs.
• Encourage home BP logs to guide titration and assess adherence.
• Regularly reassess lifestyle measures, cardiovascular risk factors (lipids, glucose), and target-organ status.

Key Clinical Pearls for Exams and Practice

• Hypertension is usually asymptomatic—do not wait for symptoms to treat; focus on BP values and risk profile.
• Confirm diagnosis with repeated office measurements and, when available, ABPM or HBPM to rule out white-coat or masked hypertension.[7](https://europepmc.org/article/MED/41809280)
• Always think of secondary causes in younger patients, severe or resistant HTN, or when clinical clues (hypokalemia, abdominal bruits, endocrine signs) are present.
• Assess and document target-organ damage at baseline: retina, heart (ECG, ± echo), kidneys (creatinine, eGFR, albuminuria).
• Combination therapy is often needed; using fixed-dose combinations can improve adherence.
• ACEI/ARB + thiazide or ACEI/ARB + CCB are common and effective combinations; avoid ACEI + ARB together due to increased risk of kidney injury and hyperkalemia.
• Lifestyle modification is foundational and should be continued even when medications are started; it can reduce pill burden and improve long-term outcomes.[7](https://europepmc.org/article/MED/41809280)
• Education and engagement are key in young and student populations, where modifiable behaviors (diet, activity, sleep, substance use) heavily influence BP.[7](https://europepmc.org/article/MED/41809280)
• Remember that hypertension clusters with other non-communicable diseases (diabetes, dyslipidemia, obesity); management should address global cardiovascular risk rather than BP in isolation.[7](https://europepmc.org/article/MED/41809280)

Summary

Hypertension is a highly prevalent, often silent condition that substantially increases the risk of cardiovascular, cerebrovascular, and renal disease. Accurate diagnosis, thorough evaluation for secondary causes and target-organ damage, aggressive modification of lifestyle factors, and appropriate pharmacologic therapy are essential to reduce morbidity and mortality. For medical students, mastering the definitions, mechanisms, diagnostic approach, and management strategies for hypertension is foundational for clinical practice and high-yield for examinations.[7](https://europepmc.org/article/MED/41809280)